1-4 of 4 results for subject:Shingles
Librarians' tools
- Search time
- 0.208 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Shingles
- We searched for
- subject_t:Shingles OR subject_ses:429833
Type
House
Session
Month
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health what assessment he has made of the potential value of shingles vaccinations for people aged between 70 and 79 years.
To ask the Secretary of State for Health what assessment he has made of the potential value of shingles vaccinations for people aged between 70 and 79 years.
The Department is advised on matters concerning vaccination and immunisation by the independent committee, the Joint Committee on Vaccination and Immunisation (JCVI). The JCVI reviewed the medical, epidemiological, and economic evidence as well as vaccine safety and efficacy data relevant to a herpes zoster (shingles) vaccination programme and recommended that a universal herpes zoster vaccination programme for adults aged 70, up to and including 79 years, be introduced, provided that a licensed vaccine was available at a cost-effective price.
Around 30,000 people in their 70s in England and Wales are affected by shingles each year. One in 1,000
people over 70 who get shingles dies of the infection. Reducing the number affected by shingles will not only save lives but also reduce the pressure on general practitioners and hospitals and reduce the pain suffered by the patient.
To ask Her Majesty’s Government why the shingles catch up scheme is available from April 2013 for patients aged 70 but not yet 71 and from 1 September 2013 for patients aged 79 on that date, but not available for patients between 71 and 79.[HL2397]
To ask Her Majesty’s Government why the shingles catch up scheme is available from April 2013 for patients aged 70 but not yet 71 and from 1 September 2013 for patients aged 79 on that date, but not available for patients between 71 and 79.[HL2397]
The Joint Committee on Vaccination and Immunisation (JCVI) has recommended a universal herpes zoster (shingles) vaccination programme for adults aged 70 years up to and including 79 years. Zostavax® vaccine is the only market authorised shingles vaccine available in the United Kingdom.
In 2013-14, supplies of the vaccine have been secured sufficient for the routine vaccination of adults aged 70 and for those aged 79 years on a 'catch-up' basis. This is a standard approach to the introduction of a new vaccination programme where initial supplies of vaccine are limited. It allows vaccination of the optimum number of people and ensures we are able to use National Health Service resources to provide the greatest benefit from the amount of vaccine available.
It is not possible to extend provision to patients aged 71 and 78 years in the current 2013-14 vaccination season. There will be a progressive programme to vaccinate all those in the recommended age groups. This will mean that in the longer term all of those aged between 70 and 79 will be able to receive the vaccine. How quickly that can be achieved is dependent in part on the availability of shingles vaccine in coming years; we are actively assessing that availability.
To ask the Secretary of State for Health if he will extend the provision of shingles vaccinations to patients aged 71 to 78.
To ask the Secretary of State for Health if he will extend the provision of shingles vaccinations to patients aged 71 to 78.
The Joint Committee on Vaccination and Immunisation has recommended a universal herpes zoster (shingles) vaccination programme for adults aged 70 years up to and including 79 years. Zostavax® vaccine is the only market authorised shingles vaccine available in the United Kingdom.
In 2013-14, supplies of the vaccine have been secured sufficient for the routine vaccination of adults aged 70 and for those aged 79 years on a ‘catch-up’ basis. This is a standard approach to the introduction of a new vaccination programme where initial supplies of vaccine are limited. It allows vaccination of the optimum number of people and ensures we are able to use national health service resources to provide the greatest benefit from the amount of vaccine available.
It is not possible to extend provision to patients aged 71 and 78 years in the current 2013-14 vaccination season. There will be a progressive programme to vaccinate all those in the recommended age groups. This will mean that in the longer term all of those aged between 70 and 79 will be able to receive the vaccine. How quickly that can be achieved is dependent in part on the availability of shingles vaccine in coming years .
To ask the Secretary of State for Health what assessment he has made of the benefit to public health of extending the provision of shingles vaccinations to those aged 71 to 78.
To ask the Secretary of State for Health what assessment he has made of the benefit to public health of extending the provision of shingles vaccinations to those aged 71 to 78.
The Joint Committee on Vaccination and Immunisation reviewed the medical, epidemiological, and economic evidence, as well as vaccine safety and efficacy data relevant to a herpes zoster (shingles) vaccination programme, and recommended that a universal herpes zoster vaccination programme for adults aged 70 up to and including 79 years be introduced, provided that a licensed vaccine was available at a cost effective price. Zostavax® vaccine is the only market authorised shingles vaccine available in the United Kingdom.
A routine herpes zoster vaccination programme for those aged 70 began in England on 1 September 2013. A catch-up programme for the vaccination of those aged 71 to 79 years will also be undertaken, with those aged 79 to be offered the vaccine this year. Those aged 71 to 78 will be offered vaccination in future years, dependent upon vaccine availability.